Veradermics is now public with a billion dollar market cap. 2/7/2026
Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity What to look Forward to in 2025
Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community The future of hair loss drugs.
Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.
community What new hair-loss treatments actually look exciting right now (Oct 2025)
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
Related Research
6 / 6 results
research A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
This review highlights the significant psychosocial impact of alopecia areata on children and adolescents, affecting self-esteem, relationships, academic performance, and the well-being of their families.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.
research Evaluating the Quality of TikTok Content on Alopecia: A Cross-Sectional DISCERN-Based Analysis
This study found that alopecia-related content on TikTok is generally low in quality, with dermatologist-created videos being higher quality but receiving less engagement compared to personal experience videos.
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research The Intersection of Sleep and Hair Loss: A Systematic Review
This study suggests a possible bidirectional relationship between sleep quality and hair loss, indicating that addressing sleep disturbances might improve hair loss management and patient well-being.
research Emerging pharmacotherapies for Androgenetic Alopecia
This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.